Trenchant BioSystems struck an engineering and development collaboration with Invetech to advance its AutoCell platform toward commercialization, targeting fully automated, point‑of‑care cell and gene therapy (CGT) manufacturing. The companies said internal and independent data support AutoCell’s potential to cut or eliminate ex vivo expansion steps and to produce T cells from a single unit of whole blood. Invetech will provide development and manufacturing expertise as Trenchant aims for an early‑access launch in 2027 and full commercial release later that year. Executives framed the deal as a route to reduce costs of goods, shorten manufacturing timelines, and enable distributed CGT production at treatment centers. Source: Trenchant and Invetech joint announcement.